Yoko Wada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoko Wada has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Ichiei Narita
Niigata University
12 shared publications - Masaaki Nakano
Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, 2-746 Asahimachi-Dori, Chuo-ku, Niigata City 951-8518, Japan
10 shared publications Ichiei Narita
Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-ku, Niigata, 951-8510, Japan
8 shared publications- Takeshi Kuroda
Niigata University Health Administration Center, 2-8050 Ikarashi, Nishi-ku, Niigata City 950-2181, Japan
8 shared publications Masaaki Nakano
School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
7 shared publications- Takeshi Nakatsue
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-ku, Niigata City 951-8510, Japan
7 shared publications
Latest Publications
- Open Access
- 10 July 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (9) , ziae090
Incidence and clinical course of femoral localized periosteal thickening and atypical femoral fracture over a 10-year period in patients with autoimmune inflammatory rheumatic disease
Atypical femoral fracture (AFF) is generally a rare complication of long-term use of bisphosphonate (BP); glucocorticoid (GC) use and Asian race are also risk factors. Femoral localized periosteal thickening (LPT, also termed “beaking”) of the lateral cortex often precedes AFF. This cohort study investigated the incidence of LPT and AFF and their clinical courses over 10 yr in patients with autoimmune inflammatory rheumatic diseases (AIRDs) treated with BP and GC. The study population consisted of 121 patients with AIRDs taking BP and GC. LPT was screened by X-ray, and the LPT shape was evaluated. Prednisolone (PSL) dose was 10 (8–12) mg/d at enrollment and 9 (6–10) mg/d at the last observation. LPT was evident in 10 patients at enrollment and increased linearly to 31 patients (26%) at the last observation. AFF occurred in 9 femurs of 5 patients with LPT. All patients with AFF had bilateral LPT, and the prevalence of pointed type and LPT height were higher in the AFF-positive group than in the AFF-negative group. AFF occurred before BP discontinuation in 2 patients, 1 yr after BP discontinuation in 1, after BP discontinuation followed by 7 yr of alfacalcidol use in 1, and after switching from alfacalcidol to denosumab in 1. The prevalence rates of AFF and LPT associated with long-term BP use with concomitant use of GC (mostly PSL ≥ 6 mg/d) in Japanese patients with AIRD increased over time. The selection of long-term osteoporosis treatment for LPT-positive patients is difficult in some cases.
- 10 July 2024
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (9) , ziae090
Open AccessIncidence and clinical course of femoral localized periosteal thickening and atypical femoral fracture over a 10-year period in patients with autoimmune inflammatory rheumatic disease
Atypical femoral fracture (AFF) is generally a rare complication of long-term use of bisphosphonate (BP); glucocorticoid (GC) use and Asian race are also risk factors. Femoral localized periosteal thickening (LPT, also termed “beaking”) of the lateral cortex often precedes AFF. This cohort study investigated the incidence of LPT and AFF and their clinical courses over 10 yr in patients with autoimmune inflammatory rheumatic diseases (AIRDs) treated with BP and GC. The study population consisted of 121 patients with AIRDs taking BP and GC. LPT was screened by X-ray, and the LPT shape was evaluated. Prednisolone (PSL) dose was 10 (8–12) mg/d at enrollment and 9 (6–10) mg/d at the last observation. LPT was evident in 10 patients at enrollment and increased linearly to 31 patients (26%) at the last observation. AFF occurred in 9 femurs of 5 patients with LPT. All patients with AFF had bilateral LPT, and the prevalence of pointed type and LPT height were higher in the AFF-positive group than in the AFF-negative group. AFF occurred before BP discontinuation in 2 patients, 1 yr after BP discontinuation in 1, after BP discontinuation followed by 7 yr of alfacalcidol use in 1, and after switching from alfacalcidol to denosumab in 1. The prevalence rates of AFF and LPT associated with long-term BP use with concomitant use of GC (mostly PSL ≥ 6 mg/d) in Japanese patients with AIRD increased over time. The selection of long-term osteoporosis treatment for LPT-positive patients is difficult in some cases.
- 25 April 2018
- Published by The Japan Geriatrics Society in Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
- Vol. 55 (2) , 251-258
The treatment of patients with elderly-onset rheumatoid arthritis at Niigata Rheumatic Center
目的:当院における高齢発症関節リウマチ(RA)症例の初期治療と臨床経過を明らかにする.方法:1.80歳以上でRAを発症した55例(高齢発症群)の診断時背景,初期治療内容,治療反応性,合併症を調査し,40~59歳で発症した119例(非高齢発症群)と比較した.2.80歳以上でRAを発症し当院で生物学的製剤を導入された19例の導入時背景,治療反応性,合併症を調査した.結果:1.高齢発症群の診断時平均DAS28-ESR(DAS),HAQ-DI(HAQ)は非高齢発症群より有意に高かった(4.91±1.31 vs 4.41±1.47,p=0.043,1.2±0.9 vs 0.5±0.6,p<0.01).高齢発症群では初期治療として87.3%に従来型合成抗リウマチ薬(csDMARDs)が使用されたがMTX使用例はなかった.56.4%にプレドニゾロン(PSL)が使用され非高齢発症群より有意に高率であった(p<0.01).3,6カ月後両群ともDAS,HAQは有意に低下したがHAQは高齢発症群で高かった.PSL導入例31例は非導入例24例に比べ3カ月でDAS,HAQが有意に大きく低下した(ΔDAS:2.55±1.83 vs 1.83±1.23,p<0.01,ΔHAQ:0.9±1.0 vs 0.3±0.6,p=0.027).感染症合併は高齢発症群で多かった.2.19例の導入時DASは4.93±1.17,HAQは1.5±1.0であった.このうち6カ月間観察できた15例のDAS,HAQは6カ月後有意に低下した.考察:当院では高齢発症例でMTX使用率が低く大部分はMTX以外のcsDMARDsとPSL併用で短期的な疾患活動性低下や身体機能改善を得られたが生物学的製剤を要する重症例もあった.現在高齢発症RA治療の明確な推奨はないが合併症リスクへの配慮と速やかな疾患コントロールをどのように目指すべきか,今後の検討課題と考えられた.
- 25 April 2018
- Published by The Japan Geriatrics Society in Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
- Vol. 55 (2) , 251-258
The treatment of patients with elderly-onset rheumatoid arthritis at Niigata Rheumatic Center
目的:当院における高齢発症関節リウマチ(RA)症例の初期治療と臨床経過を明らかにする.方法:1.80歳以上でRAを発症した55例(高齢発症群)の診断時背景,初期治療内容,治療反応性,合併症を調査し,40~59歳で発症した119例(非高齢発症群)と比較した.2.80歳以上でRAを発症し当院で生物学的製剤を導入された19例の導入時背景,治療反応性,合併症を調査した.結果:1.高齢発症群の診断時平均DAS28-ESR(DAS),HAQ-DI(HAQ)は非高齢発症群より有意に高かった(4.91±1.31 vs 4.41±1.47,p=0.043,1.2±0.9 vs 0.5±0.6,p<0.01).高齢発症群では初期治療として87.3%に従来型合成抗リウマチ薬(csDMARDs)が使用されたがMTX使用例はなかった.56.4%にプレドニゾロン(PSL)が使用され非高齢発症群より有意に高率であった(p<0.01).3,6カ月後両群ともDAS,HAQは有意に低下したがHAQは高齢発症群で高かった.PSL導入例31例は非導入例24例に比べ3カ月でDAS,HAQが有意に大きく低下した(ΔDAS:2.55±1.83 vs 1.83±1.23,p<0.01,ΔHAQ:0.9±1.0 vs 0.3±0.6,p=0.027).感染症合併は高齢発症群で多かった.2.19例の導入時DASは4.93±1.17,HAQは1.5±1.0であった.このうち6カ月間観察できた15例のDAS,HAQは6カ月後有意に低下した.考察:当院では高齢発症例でMTX使用率が低く大部分はMTX以外のcsDMARDsとPSL併用で短期的な疾患活動性低下や身体機能改善を得られたが生物学的製剤を要する重症例もあった.現在高齢発症RA治療の明確な推奨はないが合併症リスクへの配慮と速やかな疾患コントロールをどのように目指すべきか,今後の検討課題と考えられた.
- Open Access
- 5 March 2018
- Published by Springer Nature in BMC Research Notes
- Vol. 11 (1) , 1-7
Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis—possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report
Visceral disseminated varicella zoster viral (VZV) infection is a rare but severe complication with a high mortality rate in immunosuppressed individuals, and an increased susceptibility to VZV has been reported in kidney transplant recipients who are treated with mycophenolate mofetil (MMF). In Japan, MMF is currently approved for patients with lupus nephritis (LN) and data to indicate its optimal dosage are still insufficient. A 46-year-old Japanese woman with rheumatoid arthritis was diagnosed as having systemic lupus erythematosus (SLE) and LN class III (A/C). Although initial remission-induction therapy with prednisolone and tacrolimus was started, her serum creatinine level and urinary protein excretion were elevated. Methylprednisolone pulse therapy was added, and tacrolimus was switched to MMF. Two months after admission when she was taking 40 mg of PSL and 1500 mg of MMF daily, she suddenly developed upper abdominal pain and multiple skin blisters, and disseminated visceral VZV infection was diagnosed. Laboratory examinations demonstrated rapid exacerbation of severe acute liver failure and coagulation abnormalities despite immediate multidisciplinary treatment, and she died of hemorrhagic shock 7 days after the onset of abdominal pain. A serum sample collected at the time of admission revealed that she had recursive VZV infection. MMF together with high-dose glucocorticoid therapy may increase the risk of VZV infection in Asian patients with SLE. Accumulation of evidence for parameters of safety, such as the area under the blood concentration–time curve of mycophenolic acid, should be urgently considered in order to establish a safer protocol for remission induction therapy in Asian patients with LN.
- 5 March 2018
- Published by Springer Nature in BMC Research Notes
- Vol. 11 (1) , 1-7
Open AccessFatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis—possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report
Visceral disseminated varicella zoster viral (VZV) infection is a rare but severe complication with a high mortality rate in immunosuppressed individuals, and an increased susceptibility to VZV has been reported in kidney transplant recipients who are treated with mycophenolate mofetil (MMF). In Japan, MMF is currently approved for patients with lupus nephritis (LN) and data to indicate its optimal dosage are still insufficient. A 46-year-old Japanese woman with rheumatoid arthritis was diagnosed as having systemic lupus erythematosus (SLE) and LN class III (A/C). Although initial remission-induction therapy with prednisolone and tacrolimus was started, her serum creatinine level and urinary protein excretion were elevated. Methylprednisolone pulse therapy was added, and tacrolimus was switched to MMF. Two months after admission when she was taking 40 mg of PSL and 1500 mg of MMF daily, she suddenly developed upper abdominal pain and multiple skin blisters, and disseminated visceral VZV infection was diagnosed. Laboratory examinations demonstrated rapid exacerbation of severe acute liver failure and coagulation abnormalities despite immediate multidisciplinary treatment, and she died of hemorrhagic shock 7 days after the onset of abdominal pain. A serum sample collected at the time of admission revealed that she had recursive VZV infection. MMF together with high-dose glucocorticoid therapy may increase the risk of VZV infection in Asian patients with SLE. Accumulation of evidence for parameters of safety, such as the area under the blood concentration–time curve of mycophenolic acid, should be urgently considered in order to establish a safer protocol for remission induction therapy in Asian patients with LN.
- 25 October 2017
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 22 (3) , 597-602
Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus
Using a single-center cohort of Japanese patients with SLE, we attempted to clarify the long-term outcome and factors associated with damage accrual using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).
- 25 October 2017
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 22 (3) , 597-602
Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus
Using a single-center cohort of Japanese patients with SLE, we attempted to clarify the long-term outcome and factors associated with damage accrual using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).
- Open Access
- 4 October 2017
- Published by Wiley in Journal of Hospital Medicine
- Vol. 12 (12) , 989-993
A Strong Diagnosis of Weakness
The approach to clinical conundrums by an expert clinician is revealed through the presentation of an actual patient's case in an approach typical of a morning report. Similar to patient care, sequential pieces of information are provided to the clinician, who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant.
- 4 October 2017
- Published by Wiley in Journal of Hospital Medicine
- Vol. 12 (12) , 989-993
Open AccessA Strong Diagnosis of Weakness
The approach to clinical conundrums by an expert clinician is revealed through the presentation of an actual patient's case in an approach typical of a morning report. Similar to patient care, sequential pieces of information are provided to the clinician, who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant.
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 151-152
Significant association between renal function and area of amyloid deposition evident in kidney biopsy specimens in both AA and AL amyloidosis
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 151-152
Significant association between renal function and area of amyloid deposition evident in kidney biopsy specimens in both AA and AL amyloidosis
- 12 November 2016
- Published by Springer Nature
- p. 303-311
A Case of Concurrent IgG4-Related Kidney Disease and Lupus Nephritis
- 12 November 2016
- Published by Springer Nature
- p. 303-311
A Case of Concurrent IgG4-Related Kidney Disease and Lupus Nephritis
- Open Access
- 26 April 2016
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 240
Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report
Pneumocystis jirovecii pneumonia (PCP) is potentially fatal infectious complication in patients with rheumatoid arthritis (RA) during immunosuppressive therapy. Hospital survival due to human immunodeficiency virus—unrelated PCP reaches to 60 %. The high mortality rate results from difficulties in establishing an early diagnosis, concurrent use of prophylactic drugs, possible bacterial coinfection. We herein report a case of PCP in RA patients who developed the architectural distortions of lung in spite of combined modality therapy. A 73-year-old Japanese woman with RA was admitted with shortness of breath. Five weeks previously, she had been started on etanercept in addition to methotrexate (MTX). Chest computed tomography (CT) demonstrated diffuse ground glass opacities distributed throughout the bilateral middle to lower lung fields, and serum β-d-glucan was elevated. Bronchoalveolar lavage fluid revealed no P. jirovecii, but the organism was detected by polymerase chain reaction method. Trimethoprim/sulfamethoxazole was administered with methylprednisolone pulse therapy. However, the follow-up chest X-ray and chest CT demonstrated aggravation of the pneumonia with architectural distortions. Additional direct hemoperfusion with polymyxin B-immobilized fibers and intravenous cyclophosphamide therapy were insufficiently effective, and the patient died on day 25. The architectural distortions of lung should be considered as a cause of death of PCP. For this reason, a high suspicion of this infectious complication must be kept in mind in order to establish an early diagnosis and treatment in patients with RA managed with MTX and biologics.
- 26 April 2016
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 240
Open AccessAcute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report
Pneumocystis jirovecii pneumonia (PCP) is potentially fatal infectious complication in patients with rheumatoid arthritis (RA) during immunosuppressive therapy. Hospital survival due to human immunodeficiency virus—unrelated PCP reaches to 60 %. The high mortality rate results from difficulties in establishing an early diagnosis, concurrent use of prophylactic drugs, possible bacterial coinfection. We herein report a case of PCP in RA patients who developed the architectural distortions of lung in spite of combined modality therapy. A 73-year-old Japanese woman with RA was admitted with shortness of breath. Five weeks previously, she had been started on etanercept in addition to methotrexate (MTX). Chest computed tomography (CT) demonstrated diffuse ground glass opacities distributed throughout the bilateral middle to lower lung fields, and serum β-d-glucan was elevated. Bronchoalveolar lavage fluid revealed no P. jirovecii, but the organism was detected by polymerase chain reaction method. Trimethoprim/sulfamethoxazole was administered with methylprednisolone pulse therapy. However, the follow-up chest X-ray and chest CT demonstrated aggravation of the pneumonia with architectural distortions. Additional direct hemoperfusion with polymyxin B-immobilized fibers and intravenous cyclophosphamide therapy were insufficiently effective, and the patient died on day 25. The architectural distortions of lung should be considered as a cause of death of PCP. For this reason, a high suspicion of this infectious complication must be kept in mind in order to establish an early diagnosis and treatment in patients with RA managed with MTX and biologics.
- 18 September 2015
- Published by Springer Nature in Clinical Rheumatology
- Vol. 34 (12) , 2071-2077
High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus
The purpose of this study was to clarify the factors related to silent osteonecrosis of the femoral head (ONFH) in patients with systemic lupus erythematosus (SLE). Seventy-eight patients with SLE were selected on the basis of having been newly diagnosed and requiring high-dose prednisolone, including pulse therapy with methylprednisolone, as the initial treatment. All the patients initially underwent MRI at 3 months after the start of corticosteroid treatment to detect any early changes in the femoral head. These examinations were then performed again 3 months later. Laboratory parameters were evaluated at the start of steroid treatment and at 1 month thereafter. By 3 months after the start of corticosteroid treatment, silent ONFH was diagnosed by MRI in 21 patients (26.9 %), being bilateral in 11 patients and unilateral in 10. The occurrence of silent ONFH was not related to SLE disease activity index, serological activity, or renal function; it was also unrelated to body mass index (BMI), body surface area (BSA), and the initial dose of prednisolone per unit body weight. However, the total cholesterol level at 4 weeks after the start of steroid treatment tended to be higher in patients with silent ONFH. Patients with a higher triglyceride level showed a significantly higher frequency of silent ONFH both before (p = 0.002) and 4 weeks after (p = 0.036) steroid initiation. A high triglyceride level is an important risk factor for silent ONFH in patients with SLE, and large-scale epidemiologic surveys of such early events are needed in this patient population.
- 18 September 2015
- Published by Springer Nature in Clinical Rheumatology
- Vol. 34 (12) , 2071-2077
High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus
The purpose of this study was to clarify the factors related to silent osteonecrosis of the femoral head (ONFH) in patients with systemic lupus erythematosus (SLE). Seventy-eight patients with SLE were selected on the basis of having been newly diagnosed and requiring high-dose prednisolone, including pulse therapy with methylprednisolone, as the initial treatment. All the patients initially underwent MRI at 3 months after the start of corticosteroid treatment to detect any early changes in the femoral head. These examinations were then performed again 3 months later. Laboratory parameters were evaluated at the start of steroid treatment and at 1 month thereafter. By 3 months after the start of corticosteroid treatment, silent ONFH was diagnosed by MRI in 21 patients (26.9 %), being bilateral in 11 patients and unilateral in 10. The occurrence of silent ONFH was not related to SLE disease activity index, serological activity, or renal function; it was also unrelated to body mass index (BMI), body surface area (BSA), and the initial dose of prednisolone per unit body weight. However, the total cholesterol level at 4 weeks after the start of steroid treatment tended to be higher in patients with silent ONFH. Patients with a higher triglyceride level showed a significantly higher frequency of silent ONFH both before (p = 0.002) and 4 weeks after (p = 0.036) steroid initiation. A high triglyceride level is an important risk factor for silent ONFH in patients with SLE, and large-scale epidemiologic surveys of such early events are needed in this patient population.
- Open Access
- 28 August 2015
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (12) , 2229
Atypical skin involvement in Erdheim–Chester disease: Fig. 1
A 49-year-old woman was referred to our hospital because of oedema of the lower extremities and exertional dyspnoea. On physical examination, multiple subcutaneous nodules from the neck to the trunk were observed (Fig. 1A). Serum biochemistry showed hypoalbuminaemia, and CRP was within normal limits. CT demonstrated numerous subcutaneous mediastinal and intra-abdominal small granular nodules, with periaortic thickening and pulmonary effusion (Fig. 1B and C). PET-CT revealed uptake of fludeoxyglucose in the bilateral femoral and lower leg bones and multiple subcutaneous nodules (Fig. 1D). A biopsy specimen from the skin nodules demonstrated foamy monocyte hyperplasia, and immunohistochemistry revealed these cells as positive for CD68 and CD163 and negative for CD1a and S100. She was negative for BRAFV600E mutation. Currently she has been in stable with IFN-α therapy.
- 28 August 2015
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (12) , 2229
Open AccessAtypical skin involvement in Erdheim–Chester disease: Fig. 1
A 49-year-old woman was referred to our hospital because of oedema of the lower extremities and exertional dyspnoea. On physical examination, multiple subcutaneous nodules from the neck to the trunk were observed (Fig. 1A). Serum biochemistry showed hypoalbuminaemia, and CRP was within normal limits. CT demonstrated numerous subcutaneous mediastinal and intra-abdominal small granular nodules, with periaortic thickening and pulmonary effusion (Fig. 1B and C). PET-CT revealed uptake of fludeoxyglucose in the bilateral femoral and lower leg bones and multiple subcutaneous nodules (Fig. 1D). A biopsy specimen from the skin nodules demonstrated foamy monocyte hyperplasia, and immunohistochemistry revealed these cells as positive for CD68 and CD163 and negative for CD1a and S100. She was negative for BRAFV600E mutation. Currently she has been in stable with IFN-α therapy.